Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov;121(5):575-579.
doi: 10.1016/j.anai.2018.06.018. Epub 2018 Jun 27.

Understanding caregiver goals, benefits, and acceptable risks of peanut allergy therapies

Matthew Greenhawt  1 , Rebekah Marsh  2 , Hannah Gilbert  3 , Scott Sicherer  4 , Audrey DunnGalvin  5 , Dan Matlock  6
Affiliations

Understanding caregiver goals, benefits, and acceptable risks of peanut allergy therapies

Matthew Greenhawt et al. Ann Allergy Asthma Immunol. 2018 Nov.

Abstract

Background: Both oral immunotherapy (OIT) and epicutaneous immunotherapy (EPIT) are emerging potential treatments for peanut allergy. Caregiver goals and expectations of these therapies are poorly defined.

Objective: To determine caregiver goals and expectations of food allergy therapy.

Methods: Twenty-two detailed, semistructured interviews of OIT and EPIT caregivers were conducted, allowing caregivers to describe their motivations for and experiences with food allergy therapy and life with a peanut allergic child.

Results: In this sample, caregivers of peanut allergic children enrolled in OIT or EPIT phase 3 trials expressed a primary goal for their child to develop a buffer against an unintentional peanut exposure. The perception of the buffer varied, representing a decreased reaction severity on exposure, increased time to react to allow for assessment, or increased threshold of peanut exposure tolerated. Although caregivers expressed that a buffer may increase their confidence in travel and dining outside the home, they do not anticipate this buffer would lessen their overall level of pretherapy anxiety, allergen-associated vigilance, or avoidance practices. Most of the caregivers hope the buffer will increase their and their child's perceived sense of freedom for the child's actions and social interactions, translating to quality of life improvement, while still respecting the limitations of having a severe allergy that has been partially treated. No caregiver viewed these therapies as a cure, and most viewed treatment as a supplement to their current avoidance practices.

Conclusion: Caregivers of peanut allergic children strongly desire that OIT and EPIT result in a buffer against an unintentional reaction, although most admitted that this would not significantly change their anxiety and family's current lifestyle.

PubMed Disclaimer

Comment in

Similar articles

See all similar articles

Cited by

  • Food Allergen Immunotherapy in the Treatment of Patients with IgE-Mediated Food Allergy.
    Turkalj M, Miletić Gospić A, Višekruna Džidić I, Banić I. Turkalj M, et al. Medicina (Kaunas). 2024 Jan 9;60(1):121. doi: 10.3390/medicina60010121. Medicina (Kaunas). 2024. PMID: 38256382 Free PMC article. Review.
  • Palforzia for Peanut Allergy: A Narrative Review and Update on a Novel Immunotherapy.
    Borne GE, Daniel CP, Wagner MJ, Plaisance CJ, Nolen A, Kelkar RA, Ahmadzadeh S, Myrcik D, Shekoohi S, Kaye AD, Varrassi G. Borne GE, et al. Cureus. 2023 Dec 13;15(12):e50485. doi: 10.7759/cureus.50485. eCollection 2023 Dec. Cureus. 2023. PMID: 38222206 Free PMC article. Review.
  • Open-label study of the efficacy, safety, and durability of peanut sublingual immunotherapy in peanut-allergic children.
    Kim EH, Keet CA, Virkud YV, Chin S, Ye P, Penumarti A, Smeekens J, Guo R, Yue X, Li Q, Kosorok MR, Kulis MD, Burks AW. Kim EH, et al. J Allergy Clin Immunol. 2023 Jun;151(6):1558-1565.e6. doi: 10.1016/j.jaci.2023.01.036. Epub 2023 Feb 23. J Allergy Clin Immunol. 2023. PMID: 36828080 Free PMC article. Clinical Trial.
  • Managing food allergy: GA2LEN guideline 2022.
    Muraro A, de Silva D, Halken S, Worm M, Khaleva E, Arasi S, Dunn-Galvin A, Nwaru BI, De Jong NW, Rodríguez Del Río P, Turner PJ, Smith P, Begin P, Angier E, Arshad H, Ballmer-Weber B, Beyer K, Bindslev-Jensen C, Cianferoni A, Demoulin C, Deschildre A, Ebisawa M, Fernandez-Rivas MM, Fiocchi A, Flokstra-de Blok B, Gerdts J, Gradman J, Grimshaw K, Jones C, Lau S, Loh R, Alvaro Lozano M, Makela M, Marchisotto MJ, Meyer R, Mills C, Nilsson C, Nowak-Wegrzyn A, Nurmatov U, Pajno G, Podestà M, Poulsen LK, Sampson HA, Sanchez A, Schnadt S, Szajewska H, Van Ree R, Venter C, Vlieg-Boerstra B, Warner A, Wong G, Wood R, Zuberbier T, Roberts G; GA2LEN Food Allergy Guideline Group; GALEN Food Allergy Guideline Group. Muraro A, et al. World Allergy Organ J. 2022 Sep 7;15(9):100687. doi: 10.1016/j.waojou.2022.100687. eCollection 2022 Sep. World Allergy Organ J. 2022. PMID: 36119657 Free PMC article. Review.
  • Psychological needs and support among patients and families undergoing food oral immunotherapy.
    Polloni L, Muraro A, Bonaguro R, Toniolo A, Ballin A, Guarnaccia A, Lazzarotto F. Polloni L, et al. Clin Transl Allergy. 2022 Feb 3;12(2):e12078. doi: 10.1002/clt2.12078. eCollection 2022 Feb. Clin Transl Allergy. 2022. PMID: 35140908 Free PMC article.
See all "Cited by" articles

Publication types

LinkOut - more resources